Louis Md Brenner - Nov 15, 2021 Form 4 Insider Report for Allena Pharmaceuticals, Inc. (ALNAQ)

Role: President and CEO, Director
Signature: /s/ Kevin Brennan, attorney-in-fact
Stock symbol: ALNAQ
Transactions as of: Nov 15, 2021
Transactions value $: -$32,666
Form type: 4
Date filed: 11/17/2021, 04:00 PM
Previous filing: May 12, 2021
Next filing: Feb 2, 2022

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	ALNAQ	Common Stock	Sale	-$32.7K	-40.3K	-12.26%	$0.81^*	289K	Nov 15, 2021	Direct	F1
transaction	ALNAQ	Common Stock	Options Exercise		+126K	+61.77%		329K	Nov 15, 2021	Direct	F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	ALNAQ	Restricted Stock Units	Options Exercise	$0	-126K	-100%	$0.00^*	0	Nov 15, 2021	Common Stock	126K		Direct	F2, F3

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The sale reported on this Form 4 was effected by the Reporting Person and represents shares sold to cover tax withholding obligations in connection with the vesting of restricted stock units.
F2	Each restricted stock unit represents a contingent right to receive one share of common stock.
F3	40% shall vest on May 10, 2021 and the remaining 60% shall vest on November 10, 2021, subject to the Reporting Person's continued service through each vesting date.